Incyte to acquire Escient Pharmaceuticals for $750 M plus Escient’s remaining net cash at closing of transaction (based on customary adjustments). Closing of acquisition is anticipated in Q3’24
Acquisition will enhance Incyte’s R&D activities in Inflammation and Autoimmunity (IAI) by addition of Escient’s MRGPR antagonists, EP262 and EP547; possible launch begins in 2029
Moreover, EP262 in the P-I study showed safety and tolerability at all doses tested with no AEs & SAEs, vital signs, or ECG parameters, whereas TEAEs were mild having incidence lesser than PBO (33.3% vs. 62.5%) and did not rise with change in dose
Ref: Incyte | Image: Incyte
Related News:- Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Dermatologic Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
